GlassScriptPhysician profile
Jonathon M Woolfson
NPI 1528154465
$11,321.81
in general payments reported to CMS, 2019-2025
30 companies · $2,139 in 2025
The $2,139 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $565 · 2021: $748 · 2022: $1,130 · 2023: $904 · 2024: $5,305 · 2025: $2,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,307 · Travel and Lodging: $40.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,307.39 |
| Travel and Lodging | $40.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visioneering Technologies, INC. | $3,667.84 | 2024 | |
| Glaukos Corporation | $2,006.95 | 2020-2025 | Ce-Marked Kxla System, Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Alcon Vision LLC | $1,775.23 | 2019-2025 | Wavelight Ex500 Excimer Laser, Clareon, Wavelight Refractive Suite |
| Johnson & Johnson Surgical Vision, INC. | $639.61 | 2019-2025 | Tecnis Simplicity, Catalys System, Veritas Vision System |
| Abbvie INC. | $592.16 | 2022-2025 | |
| Sight Sciences, INC. | $296.74 | 2021-2024 | Tearcare System |
| Kala Pharmaceuticals, INC. | $295.36 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $264.98 | 2022-2025 | Infuse |
| New World Medical,INC. | $248.13 | 2024-2025 | Kahook Dual Blade, Streamline, Clearpath |
| Oyster Point Pharma, INC. | $186.41 | 2022 | |
| Carl Zeiss Meditec, INC. | $177.90 | 2023 | Artevo 800, Lumera 700 |
| Topcon Healthcare, INC. | $176.18 | 2021-2022 | |
| Rxsight INC | $132.70 | 2022-2023 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal) |
| Johnson & Johnson Vision Care, INC. | $131.78 | 2022 | |
| Harrow Eye, LLC | $122.28 | 2024-2025 | Vevye |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $104.63 | 2024 | Izervay |
| Dompe US, INC. | $92.80 | 2025 | Oxervate |
| Topcon Healthcare Solutions, INC. | $67.63 | 2021 | |
| Biotissue Holdings INC. | $47.61 | 2021-2025 | |
| Allergan, INC. | $43.25 | 2019-2021 | |
| Ivantis, INC | $41.23 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $37.41 | 2019-2021 | |
| Vantage Technology LLC | $26.52 | 2024 | |
| Sun Pharmaceutical Industries INC. | $24.87 | 2021 | |
| Thea Pharma INC. | $24.52 | 2023 | Iyuzeh |
| Ocular Therapeutix, INC. | $21.42 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.29 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Amgen INC. | $18.38 | 2024 | Tepezza |
| Eyevance Pharmaceuticals LLC | $17.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathon Woolfson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.